Top

International Journal of Clinical Oncology

Published in:

Open Access 01-10-2018 | Original Article

Early intervention using high-precision radiotherapy preserved visual function for five consecutive patients with optic nerve sheath meningioma

Authors: Toshihiko Inoue, Osamu Mimura, Norihisa Masai, Atuyuki Ohashi, Koji Ikenaga, Yoshishige Okuno, Iku Nishiguchi, Ryoongjin Oh

Published in: International Journal of Clinical Oncology | Issue 5/2018

Abstract

Background

There has been a paradigm shift in the treatment for optic nerve sheath meningioma (ONSM) from surgery to fractionated stereotactic radiotherapy (FSRT) in other countries. However, FSRT has seldom been performed in Japan. The purpose of this retrospective study is to reconfirm the effectiveness of early intervention with precision radiotherapy for ONSM reported in our previous study.

Methods

Five consecutive patients with ONSM were retrospectively analyzed. All patients underwent intensity-modulated radiotherapy (IMRT) or FSRT. They received the early interventions between 1.5 and 7 months after deterioration of the disease. The median dose was 52.8 Gy (range 46.0–59.4 Gy) and the median number of fractions was 25 (range 22–33).

Results

All patients experienced reestablishment of vision at the median follow-up time of 36 months (range 18–54 months). Four of them noted early improvement of visual deficits during the treatment course (range 2–4 weeks) and the remaining patient improved 3 weeks after completion of IMRT. The median tumor reduction was 53% (range 39–75%). One patient with diabetes mellitus developed retinal bleeding as a result of radiation retinopathy 16 months after IMRT, although the doses were acceptable. The remaining 4 patients have no late toxicity at the follow-up time of 31–54 months.

Conclusions

A paradigm shift is necessary from surgery to early intervention using precision radiotherapy for the treatment of ONSM in Japan.

Jeremić B, Wasik MW, Villà S et al (2008) Stereotactic radiation therapy in primary optic nerve sheath meningioma. In: Jeremić B, Pitz S (eds) Primary optic nerve sheath meningioma. Springer-Verlag, Berlin Heidelberg, pp 105–127CrossRef

Hamilton SN, Nichol A, Truong P et al (2017) Visual outcomes and local control after fractionated stereotactic radiotherapy for optic nerve sheath meningioma. Ophthal Plast Reconstr Surg. https://doi.org/10.1097/IOP.0000000000000914 CrossRef

Inoue T, Okuno Y, Nishiguchi I et al (2018) Rapid recovery of vision following early intervention with fractionated stereotactic radiotherapy for optic nerve sheath meningioma. Int Med Case Rep J 11:17–22. https://doi.org/10.2147/IMCRJ.S14952 CrossRefPubMedPubMedCentral

Ortiz O, Schochet SS, Kotzan JM et al (1996) Radiologic-pathologic correlation meningioma of the optic nerve sheath. Am J Neuroradiol 17:901–906PubMed

Inoue T, Masai M, Oh R-J et al (2014) Adaptive replanning intensity-modulated radiotherapy for choroidal metastasis of breast cancer using optical coherence tomography. J Radiat Res 55(3):502–508CrossRef

Inoue T, Masai N, Shiomi H et al (2016) Feasibility study of a non-invasive eye fixation and monitoring device using a right-angle prism mirror for intensity-modulated radiotherapy for choroidal melanoma. J Radiat Res 58(3):386–396PubMedCentral

Marks LB, Yorke ED, Jackson A et al (2010) Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys 76:S10–S19CrossRef

Eddleman CS, Liu JK (2007) Optic nerve sheath meningiomas: current diagnosis and treatment. Neurosurg Focus 23(5):E4CrossRef

Mafee MF, Naheedy JH (2008) Imaging diagnosis of the optic nerve sheath meningioma. In: Jeremić B, Pitz S (eds) Primary optic nerve sheath meningioma. Springer-Verlag, Berlin Heidelberg, pp 39–53

10.

Adams G, Roos D, Crompton J (2013) Radiotherapy for optic nerve sheath meningioma: a case for earlier intervention? Clin Oncol 25:356–361CrossRef

11.

Baumert BG, Villà S, Studer G et al (2004) Early improvements in vision after fractionated stereotactic radiotherapy for primary nerve sheath meningioma. Radiother Oncol 72(2):169–174CrossRef

12.

Liu JK, Forman S, Hershewe GL et al (2002) Optic nerve sheath meningiomas: visual improvement after stereotactic radiotherapy. Neurosurgery 50:950–957PubMed

13.

Maclean J, Fersht N, Brenner F et al (2013) Meningioma causing visual impairment: outcomes and toxicity after intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys 85:e179–e186CrossRef

14.

Henzel M, Gross MW, Hemm K et al (2006) Significant tumor volume reduction of meningiomas after stereotactic radiotherapy: results of a prospective multicenter study. Neurosurgery 59:1188–1194CrossRef

15.

Henzel M, Gross MW, Hemm K et al (2006) Stereotactic radiotherapy of meningiomas. Symptomatology, acute and late toxicity. Strahlenther Onkol 182:382–388CrossRef

16.

Becker G, Jeremić B, Pitz S et al (2002) Stereotactic fractionated radiotherapy in patients with optic nerve sheath meningioma. Int J Radiat Oncol Biol Phys 54:1422–1429CrossRef

17.

Sitathanee C, Dhanachai M, Poonyathalang A et al (2006) Stereotactic radiation therapy for optic nerve sheath meningioma: an experience at Ramathibodi Hospital. J Med Assoc Thai 89:1665–1669PubMed

18.

Subramanian PS, Brssler NM, Miller NR (2004) Radiation retinopathy after fractionated stereotactic radiotherapy for optic nerve sheath meningioma. Ophthalmology 111:565–567CrossRef

19.

Brada M, Bajan B, Traish D et al (1993) The long-term efficacy of conservative surgery and radiotherapy in the control of pituitary adenomas. Clin Endocrinol (Oxf) 38(6):571–578CrossRef

20.

Becker G, Kocher M, Kortmann RD et al (2002) Radiation therapy in the multimodal treatment approach of pituitary adenoma. Strahlenther Onkol 178:173–186CrossRef

21.

Goldsmith BJ, Rosenthal SA, Wara WM et al (1992) Optic neuropathy after irradiation of meningioma. Radiology 185:71–76CrossRef

22.

Parsons JT, Bova FJ, Fitzgerald CR et al (1994) Radiation optic neuropathy after megavoltage external-beam irradiation: analysis of time-dose factor. Int J Radiat Oncol Biol Phys 30:755–763CrossRef

23.

Zenda S, Kawashima M, Arahira S et al (2015) Late toxicity of proton beam therapy for patients with the nasal cavity, para-nasal sinuses, or involving the skull base malignancy: importance of long-term follow-up. Int J Clin Oncol 20(3):447–454CrossRef

24.

Hasegawa A, Mizoe J, Mizota A et al (2006) Outcomes of visual acuity in carbon ion radiotherapy: analysis of dose–volume histograms and prognostic factors. Int J Radiat Oncol Biol Phys 64:396–401CrossRef

25.

Emami B, Lyman J, Brown A et al (1991) Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol 21:109–122CrossRef

26.

Sindou M, Nebbal M, Guclu B (2015) Cavernous sinus meningiomas: imaging and surgical strategy. Adv Tech Stand Neurosurg 42:103–121. https://doi.org/10.1007/978-3-319-09066-5_6 CrossRefPubMed

27.

Fariselli L, Biroli A, Signorelli A et al (2016) The cavernous sinus meningiomas’ dilemma: surgery or stereotactic radiosurgery? Rep Pract Oncol Radiother 21(4):379–385. https://doi.org/10.1016/j.rpor.2015.05.002 CrossRefPubMed

Title: Early intervention using high-precision radiotherapy preserved visual function for five consecutive patients with optic nerve sheath meningioma
Authors: Toshihiko Inoue
Osamu Mimura
Norihisa Masai
Atuyuki Ohashi
Koji Ikenaga
Yoshishige Okuno
Iku Nishiguchi
Ryoongjin Oh
Publication date: 01-10-2018
Publisher: Springer Japan
Published in: International Journal of Clinical Oncology / Issue 5/2018
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-018-1284-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 5/2018

Feasibility study of postoperative adjuvant chemotherapy with S-1 in patients with biliary tract cancer

Low expression of CD40L in tumor-free lymph node of oral cavity cancer related with poor prognosis

Effect of post-filter anticoagulation on mortality in patients with cancer-associated pulmonary embolism

Development and external validation of a nomogram to predict high-grade papillary bladder cancer before first-time transurethral resection of the bladder tumor

How asymptomatic are early cancer patients of five organs based on registry data in Japan

The MDM2 rs937283 A > G variant significantly increases the risk of lung and gastric cancer in Chinese population

Keynote webinar | Spotlight on antibody–drug conjugates in cancer